110 related articles for article (PubMed ID: 2261881)
1. [Antineoplastic activity of combinations of cytostatics and dextran-ferrite administered to mice with leukemia P-388].
Brusentsov NA; Glazkova TIu; Iavorskaia NP; Iurchenko NIa
Eksp Onkol; 1990; 12(6):59-60. PubMed ID: 2261881
[TBL] [Abstract][Full Text] [Related]
2. Experimental combination chemotherapy of pirarubicin with various antitumor drugs against P388 murine leukemia.
Izumi H; Hirano S; Matsushita Y; Iguchi H; Tone H; Takeuchi T
Cancer Biochem Biophys; 1994 Sep; 14(2):137-49. PubMed ID: 7889494
[TBL] [Abstract][Full Text] [Related]
3. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia.
Leopold WR; Dykes DJ; Griswold DP
NCI Monogr; 1987; (5):99-104. PubMed ID: 2963231
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
7. Potentiation by vitamin A of the action of anticancer agents against murine tumors.
Nakagawa M; Yamaguchi T; Ueda H; Shiraishi N; Komiyama S; Akiyama S; Ogata J; Kuwano M
Jpn J Cancer Res; 1985 Sep; 76(9):887-94. PubMed ID: 3932288
[TBL] [Abstract][Full Text] [Related]
8. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
10. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
11. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice.
Novotny L; Rauko P; Liska J; Elford HL; Szekeres T
Cancer Lett; 2006 Feb; 233(1):178-84. PubMed ID: 15885888
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia.
Grossie VB; Rosenblum MG; Loo TL
Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of advanced breast cancer--actual results ].
Matthes ML; Lenk H; Gürtler R; Tanneberger S
Arch Geschwulstforsch; 1982 May; 52(3):241-6. PubMed ID: 6812538
[TBL] [Abstract][Full Text] [Related]
17. [Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
Uchida T; Nagahata T; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1351-6. PubMed ID: 2114829
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in breast cancer management. Combined modality (adjuvant) therapy.
Cowan K; Lippman M
Arch Intern Med; 1981 Jul; 141(8):1055-9. PubMed ID: 7018440
[No Abstract] [Full Text] [Related]
19. Concepts for controlling drug-resistant tumor cells.
Schabel FM; Skipper HE; Trader MW; Laster WR; Corbett TH; Griswold DP
Eur J Cancer (1965); 1980; Suppl 1():199-211. PubMed ID: 6947891
[No Abstract] [Full Text] [Related]
20. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
Salimtschik M; Snel S; Havsteen H; Dombernowsky P; Mouridsen HT
Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
